An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

Trial Profile

An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Ritonavir; Tipranavir
  • Indications HIV-1 infections
  • Focus Adverse reactions; Expanded access
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 11 Apr 2012 Additional trial location (El Salvador) added as reported by ClinicalTrials.gov.
    • 24 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 08 Aug 2009 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top